GlassScriptPhysician profile
Philip P Benyo
NPI 1518965664
$6,326.38
in general payments reported to CMS, 2019-2025
38 companies · $127 in 2025
The $127 reported for 2025 was less than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,119 · 2022: $1,846 · 2023: $2,203 · 2024: $31.54 · 2025: $127.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,062.58 | 2021-2023 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $927.12 | 2021-2023 | Otezla, Repatha, Prolia |
| Pfizer INC. | $520.82 | 2021-2023 | |
| Abbvie INC. | $515.34 | 2021-2024 | |
| Lilly USA, LLC | $489.32 | 2021-2023 | Mounjaro, Amyvid, Jardiance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $286.68 | 2021-2023 | Jardiance, Tradjenta, Stiolto Respimat |
| Mylan Specialty L.P. | $216.67 | 2022-2023 | Yupelri |
| Astrazeneca Pharmaceuticals LP | $209.72 | 2021-2023 | Breztri |
| Glaxosmithkline, LLC. | $180.09 | 2021-2023 | Trelegy Ellipta, Shingrix |
| Nestle Healthcare Nutrition INC. | $173.23 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $150.00 | 2021-2023 | Eliquis |
| Teva Pharmaceuticals USA, INC. | $135.08 | 2022-2023 | Austedo Xr, Austedo |
| Merck Sharp & Dohme LLC | $130.51 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $124.79 | 2022-2023 | |
| Janssen Pharmaceuticals, INC | $118.06 | 2021-2022 |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Philip Benyo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.